INmune Bio to Detail XPro1595 Registrational Strategy in Upcoming Alzheimer’s Webinar
INmune Bio Inc. - Common stock (INMB)
Company Research
Source: GlobeNewswire
Boca Raton, FL, Feb. 23, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (“INmune” or the “Company”), a late-stage biotechnology company focused on inflammation and immunology, will host a webinar focused on the registrational pathway of XPro1595 (“XPro™”) for the treatment of early Alzheimer’s disease on February 27, 2026 at 9:30 a.m. ET. Post the completion of the Phase 2 MINDFuL trial, along with feedback from the FDA in a recent End-Of-Phase 2 meeting, the Company has received alignment supporting advancement to a registrational study in patients with Alzheimer’s Disease with biomarkers of Inflammation. Webinar Focus: From Phase 2 Results to Phase 3 Readiness XPro™ is a next-generation, selective soluble TNF inhibitor designed to selectively neutralize soluble TNF (sTNF) and restore immune homeostasis in the brain, without affecting transmembrane TNF (tmTNF) or TNF receptors. The webinar will be organized around three core topics: 1. MINDFuL Trial Results and Path
Show less
Read more
Impact Snapshot
Event Time:
INMB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INMB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INMB alerts
High impacting INmune Bio Inc. - Common stock news events
Weekly update
A roundup of the hottest topics
INMB
News
- INmune Bio Inc. (INMB) Discusses XPro1595 Phase II MINDFuL Results and Registrational Strategy in Alzheimer's Disease Transcript [Seeking Alpha]Seeking Alpha
- INmune Bio Inc. (INMB) Discusses MissionEB Phase III Trial and CORDStrom as a Disease-Modifying Therapy for RDEB Transcript [Seeking Alpha]Seeking Alpha
- INmune Bio to Detail XPro1595 Registrational Strategy in Upcoming Alzheimer's Webinar [Yahoo! Finance]Yahoo! Finance
- INmune Bio Announces Upcoming Webinar to Present New Clinical Data on CORDStrom™ for RDEBGlobeNewswire
- INmune Bio submits pre-submission package for CORDStrom with MHRA [Yahoo! Finance]Yahoo! Finance
INMB
Earnings
- 10/30/25 - Beat
INMB
Sec Filings
- 2/27/26 - Form 8-K
- 2/23/26 - Form 8-K
- 2/19/26 - Form 8-K
- INMB's page on the SEC website